Delisting risk
ESLA · NASDAQ · Biotechnology

Estrella Immunopharma (ESLA)

Develops ARTEMIS T-cell therapies for B-cell malignancies.

$0.6900
At close−0.00 (−0.22%)

Breakdown13F · 13D/G · Form 4

Institutions16 holders · as of Mar 31, 202611.91%5.18M shares
Insiders2 holders · as of Aug 26, 20261.79%779.6K shares
Otherremainder86.30%37.54M shares

43.50M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Armistice Capital, LLCInstitution
9.42%4.10M13Fas of Mar 31, 2026
Cheng LiuInsiderdirector, officer: CEO
0.91%397,437Form 4filed Aug 26, 2026
Vanguard Capital Management LLCInstitution
0.88%382,46913Fas of Mar 31, 2026
Jiandong XuInsiderofficer: Chief Financial Officer
0.88%382,188Form 4filed Aug 25, 2026
Wells Fargo & Company/MNInstitution
0.61%264,38813Fas of Mar 31, 2026
Geode Capital Management, LLCInstitution
0.36%157,48513Fas of Mar 31, 2026
Vanguard Fiduciary Trust CoInstitution
0.15%64,92113Fas of Mar 31, 2026
Renaissance Technologies LLCInstitution
0.14%62,79513Fas of Mar 31, 2026
State Street CorpInstitution
0.10%43,25213Fas of Mar 31, 2026
BlackRock, Inc.Institution
0.09%39,89013Fas of Mar 31, 2026
Northern Trust CorpInstitution
0.05%19,62413Fas of Mar 31, 2026
US Bancorp \DE\Institution
0.04%16,90413Fas of Mar 31, 2026
UBS Group AGInstitution
0.03%15,07913Fas of Mar 31, 2026
Royal Bank of CanadaInstitution
0.02%6,60013Fas of Mar 31, 2026
Tower Research Capital LLC (TRC)Institution
0.01%4,85913Fas of Mar 31, 2026
Toronto Dominion BankInstitution
0.00%1,08913Fas of Mar 31, 2026
Wolverine Asset Management LLCInstitution
0.00%46813Fas of Mar 31, 2026
Morgan StanleyInstitution
0.00%113Fas of Mar 31, 2026
Eureka Therapeutics, Inc.1,2Strategic10 percent owner
58.11%25.28MForm 4filed Oct 10, 2023
Jianwei Li3Insiderofficer: Co-Chief Executive Officer
2.88%1.25MForm 4filed Mar 17, 2022
TradeUP Acquisition Sponsor LLC4Strategic10 percent owner
2.63%1.15MForm 4filed Jul 22, 2021
Hong Zhang5Insiderdirector, other: Chairperson of the Board
0.55%240,481Form 4filed Aug 23, 2024
Tao Jiang6Insiderdirector
0.02%10,000Form 4filed Jul 26, 2021
James Long4Insiderdirector
0.02%10,000Form 4filed Jul 22, 2021
Weston Twigg4Insiderdirector
0.02%10,000Form 4filed Jul 22, 2021
  1. Last filed Oct 10, 2023; leaving the company requires no filing. Not in the bar.
  2. This 25.28M-share position rests on a single filing; nothing else on file confirms it.
  3. Last filed Mar 17, 2022; leaving the company requires no filing. Not in the bar.
  4. Last filed Jul 22, 2021; leaving the company requires no filing. Not in the bar.
  5. Last filed Aug 23, 2024; leaving the company requires no filing. Not in the bar.
  6. Last filed Jul 26, 2021; leaving the company requires no filing. Not in the bar.

13F — a manager's quarterly holdings · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

16 holders · 5.18M shares · 8 new positions · 11 increased · 2 reduced · 7 closed

HolderShares% outstandingChg q/qFiled
Armistice Capital, LLC4.10M9.42%+4.10MnewMay 15, 2026
Vanguard Capital Management LLC382.5K0.88%+382.5KnewMay 15, 2026
Wells Fargo & Company/MN264.4K0.61%+264.4KnewJul 8, 2026
Geode Capital Management, LLC157.5K0.36%+47.7KMay 15, 2026
Vanguard Fiduciary Trust Co64.9K0.15%+64.9KnewMay 8, 2026
Renaissance Technologies LLC62.8K0.14%−59.7KMay 14, 2026
State Street Corp43.3K0.10%0May 15, 2026
BlackRock, Inc.39.9K0.09%+13.4KMay 13, 2026

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Armistice Capital, LLC9.99%4.28M13GMay 15, 2026

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Sep 22, 2025
Jiandong Xuofficer: Chief Financial Officer
Purchase1,000$1.1616,700
Sep 11, 2025
Jiandong Xuofficer: Chief Financial Officer
Purchase100$1.04264,588
Oct 7, 2025
Jiandong Xuofficer: Chief Financial Officer
Purchase1,000$1.33265,488

CongressHouse and Senate disclosures

Not reported.